Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18696911 | 1.00 | CYP1A2 (0.31) | CYP1A2SLC1A2SLC1A1 | |
| SCHEMBL24355486 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL24355491 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL18696859 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL24355482 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL24355490 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL11932424 | 0.88 | SLC1A2 (0.32) | SLC1A2SLC1A1 | |
| SCHEMBL18696443 | 0.84 | SLC1A2 (0.30) | SLC1A2SLC1A1 | |
| SCHEMBL10167163 | 0.82 | — | — | |
| SCHEMBL6913788 | 0.81 | MMP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-8822424-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885SLC1A2 4020/4885SLC1A1 2847/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885SLC1A2 4020/4885SLC1A1 2847/4885 |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, MRPS23 | CYP1A2 1195/4885SLC1A2 3867/4885SLC1A1 2588/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885SLC1A2 4020/4885SLC1A1 2847/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885SLC1A2 4020/4885SLC1A1 2847/4885 |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | PIGS, PIGO, NPEPPS | CYP1A2 4459/4885SLC1A2 2779/4885SLC1A1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.